P E Tarr

Summary

Publications

  1. ncbi Infections in patients with immunodeficiency with thymoma (Good syndrome). Report of 5 cases and review of the literature
    P E Tarr
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Medicine (Baltimore) 80:123-33. 2001
  2. ncbi Multidrug-resistant Corynebacterium striatum pneumonia in a heart transplant recipient
    P E Tarr
    Section of Infectious Diseases, Department of Medicine, Washington Hospital Center, Washington, DC 20010, USA
    Transpl Infect Dis 5:53-8. 2003
  3. ncbi Case report: Rectal adminstration of ivermectin to a patient with Strongyloides hyperinfection syndrome
    Philip E Tarr
    Section of Infectious Diseases, Department of Medicine, Washington Hospital Center, Washington, District of Columbia 20010, USA
    Am J Trop Med Hyg 68:453-5. 2003
  4. ncbi Hematogenous enterococcal vertebral osteomyelitis: report of 2 cases and review of the literature
    Philip E Tarr
    Washington Hospital Center, Washington, DC, USA
    J Infect 48:354-62. 2004
  5. ncbi Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study
    Jim Young
    Institut für klinisehe Epidemiologie, Universitatsspital Basel, Basel, Switzerland
    Antivir Ther 10:585-91. 2005
  6. ncbi Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures
    Sara Colombo
    Division of Clinical Pharmacology and Toxicology, University Hospital of Lausanne, Switzerland
    Antivir Ther 11:53-62. 2006

Collaborators

Detail Information

Publications6

  1. ncbi Infections in patients with immunodeficiency with thymoma (Good syndrome). Report of 5 cases and review of the literature
    P E Tarr
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Medicine (Baltimore) 80:123-33. 2001
    ..GS should be ruled out in patients with thymoma or CVID who develop severe, especially opportunistic, infections. Treatment with intravenous immune globulin is recommended for all patients with GS...
  2. ncbi Multidrug-resistant Corynebacterium striatum pneumonia in a heart transplant recipient
    P E Tarr
    Section of Infectious Diseases, Department of Medicine, Washington Hospital Center, Washington, DC 20010, USA
    Transpl Infect Dis 5:53-8. 2003
    ..Combination therapy that includes vancomycin may be the most prudent treatment for MDR C. striatum infections...
  3. ncbi Case report: Rectal adminstration of ivermectin to a patient with Strongyloides hyperinfection syndrome
    Philip E Tarr
    Section of Infectious Diseases, Department of Medicine, Washington Hospital Center, Washington, District of Columbia 20010, USA
    Am J Trop Med Hyg 68:453-5. 2003
    ..Ivermectin administered as an enema may be beneficial in patients with severe strongyloidiasis who are unable to absorb or tolerate oral therapy...
  4. ncbi Hematogenous enterococcal vertebral osteomyelitis: report of 2 cases and review of the literature
    Philip E Tarr
    Washington Hospital Center, Washington, DC, USA
    J Infect 48:354-62. 2004
    ....
  5. ncbi Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study
    Jim Young
    Institut für klinisehe Epidemiologie, Universitatsspital Basel, Basel, Switzerland
    Antivir Ther 10:585-91. 2005
    ..We report on medium-term lipid profiles (up to 5 years) for antiretroviral-naive patients starting NNRTI- and PI-based HAART in the Swiss HIV Cohort Study...
  6. ncbi Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures
    Sara Colombo
    Division of Clinical Pharmacology and Toxicology, University Hospital of Lausanne, Switzerland
    Antivir Ther 11:53-62. 2006
    ..Adding ATV to LPV caused a limited decrease in LPV concentrations. The clinical significance of this decrease is unknown and warrants further investigation to determine the need for tailoring LPV dosage in selected cases...